Leisure Capital Management Aerie Pharmaceuticals Inc Transaction History

Leisure Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 10, 2019	SELL	$28.97 - $48.21 $247,925 - $412,581	-8,558 Closed	0 $0
Q1 2019 May 08, 2019	SELL	$36.32 - $49.25 $653 - $886	-18 Reduced 0.21%	8,558 $407,000
Q4 2018 Feb 13, 2019	SELL	$33.0 - $60.04 $12,045 - $21,914	-365 Reduced 4.08%	8,576 $310,000
Q3 2018 Nov 09, 2018	SELL	$56.15 - $73.9 $52,668 - $69,318	-938 Reduced 9.49%	8,941 $550,000
Q2 2018 Aug 02, 2018	SELL	$47.85 - $70.45 $339,447 - $499,772	-7,094 Reduced 41.8%	9,879 $667,000
Q1 2018 May 11, 2018	SELL	$51.15 - $61.0 $16,009 - $19,093	-313 Reduced 1.81%	16,973 $921,000
Q4 2017 Feb 12, 2018	BUY	$50.85 - $65.1 $19,323 - $24,737	380 Added 2.25%	17,286 $1.03 Million
Q3 2017 Oct 24, 2017	SELL	$48.6 - $60.1 $111,682 - $138,109	-2,298 Reduced 11.97%	16,906 $822,000
Q2 2017 Aug 09, 2017	BUY	N/A	19,204	19,204 $1.01 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Leisure Capital Management, based on Form 13F filings with the SEC.

Stay updated on Leisure Capital Management with notifications on news.